CTIS2023-504027-78-00招募中1 期
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of RO7247669 Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy - BO44157
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 244
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2, 2. Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Patients with squamous, sarcomatoid, micropapillary, and glandular variant histologies are eligible for inclusion in the study, provided that a urothelial component is present in the tumor specimen. Patients with other variant histologies or pure variant histologies are not eligible for inclusion in the study, 3. Considered to be ineligible (unfit) to receive platinum-based chemotherapy defined by one of the following criteria: • ECOG Performance Status of 0 with baseline GFR = 15 mL/min/1.73 m2 and = 30 mL/min/1.73 m2 • ECOG Performance Status of 1 or 2 with baseline GFR = 15 mL/min/1.73 m2 and = 45 mL/min/1.73 m2 • ECOG Performance Status of 0-2 with Grade = 2 neuropathy • Patients for whom chemotherapy is not deemed appropriate, 4. No prior chemotherapy for inoperable locally advanced or metastatic or recurrent urothelial carcinoma (UC), 5. Measurable disease; at least one measurable lesion as defined by response evaluation criteria in solid tumors, version 1.1 (RECIST v1.1), 6. Availability of a representative leftover tumor specimen that meet the criteria outlined prior to study enrollment, and that is suitable for determination of programmed death-ligand 1 (PD-L1) status, for stratification and for exploratory biomarker research as assessed by a central laboratory
排除标准
- •1. Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab, 4 months after the final dose of RO7247669, or 90 days after the final dose of tiragolumab, 2. Glomerular filtration rate (GFR) < 15 mL/min/1.73 m2 as calculated through use of the chronic kidney disease epidemiology collaboration (CKD-EPI) equation or receiving dialysis, 3. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases, 4. History of leptomeningeal disease, 5. Uncontrolled tumor-related pain. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures and uncontrolled or symptomatic hypercalcemia, 6. Active or history of autoimmune disease or immune deficiency. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. Active tuberculosis (TB) or acute or chronic active Epstein-Barr virus (EBV)
研究者
相似试验
进行中（未招募）
1 期
1L NSCLC Phase II RCT M7824 vs Pembrolizumabon-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001517-32-ITMERCK KGAA300
进行中（未招募）
1 期
1L NSCLC Phase II RCT M7824 vs PembrolizumabEUCTR2018-001517-32-GRMerck KGaA300
进行中（未招募）
1 期
1L NSCLC Phase II RCT M7824 vs Pembrolizumabon-small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001517-32-ESMerck KGaA300
进行中（未招募）
1 期
A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-B, a Mixture of Two Monoclonal Antibodies, as Compared to Hepatitis B Immune Globulin in Patients who have Received Hepatic Allografts for Treatment of End-Stage Liver Disease due to Hepatitis B Virus InfectioHepatic allograft recipients for treatment of hepatitis B virus infection.EUCTR2004-000501-21-GBXTL Biopharmaceuticals75
进行中（未招募）
1 期
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHPatients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 18.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003717-29-FRAstraZeneca AB240